Medtronic (NYSE:MDT) said today that it launched a clinical trial to evaluate the use of its In.Pact paclitaxel-coated percutaneous transluminal angioplasty balloon catheter in patients with below-the-knee peripheral arterial disease.
The company treated its 1st patient in the In.Pact BTK study, performing the procedure on a patient with critical limb ischemia.
Get the full story at our sister site, Drug Delivery Business News.